Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Phase 1 Terminated 72 enrolled Regeneron Pharmaceuticals

RandomizedSingle-groupQuadruple-blindTreatment

Summary

This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of REGN1193 in patients with Type 2 Diabetes Mellitus.

Timeline

Start: 2014-10
Primary completion: 2015-12
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CROTEDUMAB	Monoclonal antibody	—	—

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications